Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment

Journal of Dermatological Science

Volumn 70, Issue 2, 2013, Pages 116-122

  Hoshina, Daichi ^a   Abe, Riichiro ^a   Yoshioka, Naoya ^a   Saito, Nao ^a   Hata, Hiroo ^a   Fujita, Yasuyuki ^a   Aoyagi, Satoru ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiosarcoma; Bevacizumab; Sunitinib; VEGF

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; MESSENGER RNA; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN C;

AGED; ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEMANGIOSARCOMA; HETEROGRAFTS; HUMANS; INDOLES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876965431     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.02.008     Document Type: Article

References (31)

1. Coindre J.M., Terrier P., Guillou L., Le Doussal V., Collin F., Ranchere D., et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001, 91:1914-1926.
2. Rouhani P., Fletcher C.D., Devesa S.S., Toro J.R. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008, 113:616-627.
3. Fayette J., Martin E., Piperno-Neumann S., Le Cesne A., Robert C., Bonvalot S., et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007, 18:2030-2036.
4. Abraham J.A., Hornicek F.J., Kaufman A.M., Harmon D.C., Springfield D.S., Raskin K.A., et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007, 14:1953-1967.
5. Masuzawa M., Fujimura T., Hamada Y., Fujita Y., Hara H., Nishiyama S., et al. Establishment of a human hemangiosarcoma cell line (ISO-HAS). Int J Cancer 1999, 81:305-308.
6. Krump-Konvalinkova V., Bittinger F., Olert J., Brauninger W., Brunner J., Kirkpatrick C.J. Establishment and characterization of an angiosarcoma-derived cell line AS-M. Endothelium 2003, 10:319-328.
7. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
8. Cao Y., Zhong W., Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009, 19:338-343.
9. Park M.S., Ravi V., Araujo D.M. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010, 22:351-355.
10. Itakura E., Yamamoto H., Oda Y., Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008, 97:74-81.
11. Tokuyama W., Mikami T., Masuzawa M., Okayasu I. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum Pathol 2010, 41:407-414.
12. Li Q., Yano S., Ogino H., Wang W., Uehara H., Nishioka Y., et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007, 13:5918-5925.
13. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
14. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
15. Zhang L., Smith K.M., Chong A.L., Stempak D., Yeger H., Marrano P., et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009, 11:426-435.
16. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., et al. Autocrine VEGF: signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
17. Masuzawa M., Mochida N., Amano T., Fujimura T., Hamada Y., Tamauchi H., et al. Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID). J Dermatol Sci 2001, 27:88-94.
18. Nakaya N., Sato I., Shimasaki T., Nakajima H., Kurose N., Nojima T., et al. A case of primary cardiac angiosarcoma associated with cardiac tamponade. Gan To Kagaku Ryoho 2011, 38:1353-1355.
19. Lopez-Barcons L.A. Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med 2010, 14:1385-1395.
20. Press J.Z., Kenyon J.A., Xue H., Miller M.A., De Luca A., Miller D.M., et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol 2008, 110:256-264.
21. Roodink I., Leenders W.P. Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett 2010, 299:1-10.
22. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
23. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896.
24. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
25. Antonescu C.R., Yoshida A., Guo T., Chang N.E., Zhang L., Agaram N.P., et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69:7175-7179.
26. Ono S., Tanioka M., Fujisawa A., Tanizaki H., Miyachi Y., Matsumura Y. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenibangiosarcoma of the scalp treated with sorafenib. Arch Dermatol 2012, 148:683-685.
27. Maki R.G., D'Adamo D.R., Keohan M.L., Saulle M., Schuetze S.M., Undevia S.D., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009, 27:3133-3140.
28. Yoo C., Kim J.E., Yoon S.K., Kim S.C., Ahn J.H., Kim T.W., et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma 2009, 360875:2009.
29. Bovee J.V., Hogendoorn P.C., Wunder J.S., Alman B.A. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010, 10:481-488.
30. Schrage Y.M., Briaire-de Bruijn I.H., de Miranda N.F., van Oosterwijk J., Taminiau A.H., van Wezel T., et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009, 69:6216-6222.
31. Morgan J.C., Majors J.E., Galileo D.S. Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation. Clin Exp Metastasis 2005, 22:167-175.